deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02437370

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

Sponsor: Merck Sharp & Dohme LLC

Conditions Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Recurrent Bladder Carcinoma Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter Regional Urothelial Carcinoma of the Renal Pelvis and Ureter Stage III Bladder Urothelial Carcinoma Stage III Urethral Cancer Stage IV Bladder Urothelial Carcinoma Stage IV Urethral Cancer Urethral Urothelial Carcinoma
Interventions Docetaxel Gemcitabine Hydrochloride Pembrolizumab
Updated 15 times since 2017 Last updated: Oct 16, 2022 Started: Sep 1, 2015 Primary completion: Aug 7, 2019 Completion: Mar 10, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02437370, this PHASE1 trial focuses on Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter and Recurrent Bladder Carcinoma and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 15 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Feb 2020 · 12 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshot~Jun 2022 – ~Oct 2022 · 4 months · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Oct 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 10 earlier versions

  1. Feb 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Feb 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  6. Feb 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  7. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  9. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of California, Davis
Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations